291 related articles for article (PubMed ID: 32297224)
1. International Valuation Protocol for the EQ-5D-Y-3L.
Ramos-Goñi JM; Oppe M; Stolk E; Shah K; Kreimeier S; Rivero-Arias O; Devlin N
Pharmacoeconomics; 2020 Jul; 38(7):653-663. PubMed ID: 32297224
[TBL] [Abstract][Full Text] [Related]
2. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
[TBL] [Abstract][Full Text] [Related]
3. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
[TBL] [Abstract][Full Text] [Related]
4. 'Like holding the axe on who should live or not': adolescents' and adults' perceptions of valuing children's health states using a standardised valuation protocol for the EQ-5D-Y-3L.
Åström M; Conte H; Berg J; Burström K
Qual Life Res; 2022 Jul; 31(7):2133-2142. PubMed ID: 35201557
[TBL] [Abstract][Full Text] [Related]
5. Using Time Trade-Off Values to Estimate EQ-5D-Y Value Sets: An Exploratory Study.
Yang Z; Jiang J; Wang P; Wu J; Fang Y; Feng D; Xi X; Luo N
Value Health; 2023 Jul; 26(7):968-973. PubMed ID: 36921897
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States.
Prevolnik Rupel V; Ramos-Goñi JM; Ogorevc M; Kreimeier S; Ludwig K; Greiner W
Value Health; 2021 Sep; 24(9):1350-1359. PubMed ID: 34452716
[TBL] [Abstract][Full Text] [Related]
7. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
[TBL] [Abstract][Full Text] [Related]
8. Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states.
Lipman SA; Reckers-Droog VT; Karimi M; Jakubczyk M; Attema AE
Eur J Health Econ; 2021 Dec; 22(9):1507-1518. PubMed ID: 34611793
[TBL] [Abstract][Full Text] [Related]
9. Value Set for the EQ-5D-Y-3L in Hungary.
Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
[TBL] [Abstract][Full Text] [Related]
10. Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?
Ramos-Goñi JM; Estévez-Carrillo A; Rivero-Arias O; Rowen D; Mott D; Shah K; Oppe M
Value Health; 2022 Jul; 25(7):1196-1204. PubMed ID: 35379562
[TBL] [Abstract][Full Text] [Related]
11. Accounting for Unobservable Preference Heterogeneity and Evaluating Alternative Anchoring Approaches to Estimate Country-Specific EQ-5D-Y Value Sets: A Case Study Using Spanish Preference Data.
Ramos-Goñi JM; Oppe M; Estévez-Carrillo A; Rivero-Arias O;
Value Health; 2022 May; 25(5):835-843. PubMed ID: 35500952
[TBL] [Abstract][Full Text] [Related]
12. Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents.
Åström M; Rolfson O; Burström K
Appl Health Econ Health Policy; 2022 May; 20(3):383-393. PubMed ID: 35083734
[TBL] [Abstract][Full Text] [Related]
13. EQ-5D-Y Value Set for Slovenia.
Prevolnik Rupel V; Ogorevc M;
Pharmacoeconomics; 2021 Apr; 39(4):463-471. PubMed ID: 33565048
[TBL] [Abstract][Full Text] [Related]
14. EQ-5D-Y as a Health-Related Quality of Life Instrument for Children and Adolescents: The Instrument's Characteristics, Development, Current Use, and Challenges of Developing Its Value Set.
Kreimeier S; Greiner W
Value Health; 2019 Jan; 22(1):31-37. PubMed ID: 30661631
[TBL] [Abstract][Full Text] [Related]
15. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
[TBL] [Abstract][Full Text] [Related]
16. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
17. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
Golicki D; Jakubczyk M; Graczyk K; Niewada M
Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
[TBL] [Abstract][Full Text] [Related]
18. Estimating an EQ-5D-Y-3L Value Set for China.
Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878
[TBL] [Abstract][Full Text] [Related]
19. Valuing EQ-5D-Y: the current state of play.
Devlin N; Pan T; Kreimeier S; Verstraete J; Stolk E; Rand K; Herdman M
Health Qual Life Outcomes; 2022 Jul; 20(1):105. PubMed ID: 35794607
[TBL] [Abstract][Full Text] [Related]
20. Valuation of the EQ-5D-3L in Russia.
Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]